VIRGINIA RETIREMENT SYSTEMS ET Al Grows Stock Holdings in Insulet Corporation $PODD

VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in Insulet Corporation (NASDAQ:PODD) by 10.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,980 shares of the medical instruments supplier’s stock after acquiring an additional 5,280 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Insulet were worth $15,343,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Winnow Wealth LLC acquired a new stake in Insulet in the third quarter valued at $862,000. Nordea Investment Management AB raised its stake in Insulet by 35.0% in the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after buying an additional 142,922 shares in the last quarter. Machina Capital S.A.S. acquired a new stake in Insulet in the third quarter valued at $2,778,000. Jain Global LLC raised its stake in Insulet by 148.2% in the third quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock valued at $32,945,000 after buying an additional 63,719 shares in the last quarter. Finally, ING Groep NV raised its stake in Insulet by 88.5% in the third quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock valued at $5,341,000 after buying an additional 8,123 shares in the last quarter.

Insulet Stock Performance

Shares of PODD stock opened at $148.84 on Thursday. The stock’s 50-day moving average is $203.70 and its two-hundred day moving average is $258.97. The firm has a market cap of $10.31 billion, a price-to-earnings ratio of 34.61, a PEG ratio of 1.29 and a beta of 1.20. Insulet Corporation has a 1 year low of $145.59 and a 1 year high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same quarter last year, the company posted $1.02 earnings per share. The business’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. Analysts predict that Insulet Corporation will post 6.44 earnings per share for the current year.

Insider Activity

In related news, Director Michael R. Minogue purchased 2,030 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were purchased at an average price of $246.23 per share, with a total value of $499,846.90. Following the completion of the acquisition, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. This represents a 13.14% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.36% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. TD Cowen lowered Insulet from a “buy” rating to a “hold” rating and set a $294.00 price objective on the stock. in a report on Monday, January 26th. Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 price objective (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Leerink Partners dropped their price objective on Insulet from $360.00 to $247.00 in a report on Thursday, May 7th. Canaccord Genuity Group dropped their price objective on Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Finally, Oppenheimer dropped their price objective on Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Nineteen investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $257.09.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.